Investigational treatment for hypertriglyceridaemia (HTG)

UniSC Clinical Trials is investigating a potential new treatment designed to evaluate the pharmacodynamic effect of RN0361 in subjects with hypertriglyceridaemia.

The trial will be overseen by Principal Investigator Dr Chris Moller at our Health Hub Morayfield clinic in Moreton Bay and supported by our experienced clinical trials staff.

We are seeking applications from people who:

• are aged between 18 and 70 years
• have a BMI between 18 and 40 kg/m²
• have triglycerides ≥ 3.38 mmol/L, and are either currently employing lifestyle management, or have been on a stable dose of lipid lowering therapy for at least 6 weeks or have had to discontinue their lipid-lowering therapy
• can attend 12 visits and one phone call at our <> clinic over approximately 10 months.

If you have patients who fit the criteria and they would be suitable for a clinical trial, we welcome referrals for patients who are interested in participating.

Eligible participants will be paid for their time on the trial.

Please do not hesitate to contact us on 07 5409 8640 for further information. We will be happy to provide you with more flyers to distribute to anyone who might be interested in participating.

Full title: A Phase 1, Randomized, Placebo-controlled, Single Ascending Dose and Phase 2 Randomized, Placebo-Controlled, Parallel-Group, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic Effects, and Immunogenicity of RN0361 in Adult Healthy Subjects and Hypertriglyceridemic Subjects

HREC approval: Bellberry Human Research Ethics Committee